Aptevo Therapeutics (APVO)Director bought ~$20K

~$20K

Approx. value · 14K sh @ $1.49

14K

Holds after · shares reported

Traded

Nov 10, 2025

Filed

Nov 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 30, 2025Company filing · Form 8-K · Material agreement, Shareholder rightsSigned an important agreement, and changed the rights of its shareholders
2. Nov 6, 2025Company filing · Form 8-K · ResultsReported its results
3. Nov 10, 2025 · this disclosureInsider · First insider buy since Nov 2020Director purchased ~$20K of APVO shares in the open market

What came next

1. Dec 29, 2025Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
2. Jan 8, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
3. Jan 30, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On January 30, 2026, Marvin L. White notified Aptevo Therapeutics Inc. (the “Company”) of his intent to retire as the Company’s President and Chief Executive Officer, effective as of April 1, 2026 (the “Transition Date”).”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Aptevo Therapeutics

OQRO holds no insider, Congress, fund or contract record for Aptevo Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its APVO page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans